Stelara 90 MG/ML syringeml
Ended Awarded Last action
- Contract number
- SPE2DR26FCYH7
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $33,168
Award facts
- Contract value 100% obligated
- $33,168.26 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $33,168.26 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Stelara 90 mg/ml syringes. The delivery order, issued on December 17, 2025, with an ultimate completion date of January 9, 2026, carries no set-aside designation, indicating the award was made through open competition. This delivery order is issued under DMS Pharmaceutical Group's larger Indefinite Delivery Contract (IDC) with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion government-wide acquisition strategy designed to streamline pharmaceutical procurement for the Department of Defense.
DMS Pharmaceutical Group holds a single-award IDC designated as contract SPE2DR, valued at $499,999,999 with a completion date of December 31, 2036. The contract structure includes a 30-month base period with three 30-month option periods and authorizes the Defense Logistics Agency to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical products, including branded and generic prescription drugs, biologics, and medical consumables to support military healthcare facilities worldwide. As a critical regional prime vendor contractor within the PPV-G GEN V framework, DMS Pharmaceutical Group has demonstrated substantial federal contracting capability through consistent performance across multiple therapeutic categories and product lines serving Department of Defense medical supply chain requirements.
Quick answers
Who was awarded contract SPE2DR26FCYH7?
SPE2DR26FCYH7 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 17, 2025.
How much is contract SPE2DR26FCYH7 worth?
The government has obligated $33,168 on SPE2DR26FCYH7.
Is contract SPE2DR26FCYH7 an order under another contract?
Yes. SPE2DR26FCYH7 is a delivery order under SPE2DR25D9153, an indefinite delivery contract.
Was contract SPE2DR26FCYH7 competed?
The extent of competition for SPE2DR26FCYH7 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award